Indivumed and Definiens Partner to Unlock the Power of Tumor Tissue for Drug Discovery and Development

Hamburg/Munich, Germany – July 21, 2016 - Definiens, the pioneer in Tissue
Phenomics solutions for diagnostics development and commercialization and
Indivumed, GmbH, based in Hamburg, Germany announce today a strategic
partnership to offer a unique combination of tissue-based biomarker validation and
assay development with Definiens Cognition Network Technology® for image
analysis and data mining.

This partnership will allow researchers and clinicians in oncology benefit from a joint
offering of Indivumed’s leading Cancer Database, Biobank and analytical laboratory
services for tissue analysis together with Definiens leading proprietary Cognition
Network Technology® and the Tissue Phenomics® approach to oncology and
diagnostics. Indivumed specializes in stringent and highly standardized tissue
collection process that preserve biomolecules such as RNA and protein, allowing
more accurate assessment of tissue patterns and more rigorous comparisons across
samples.

“Customers of either company can now benefit from this partnership and our
comprehensive approach for image analysis and tissue-based research and
development in oncology” said Hartmut Juhl, Founder and Chief Executive Officer of
Indivumed.

“In the quest to use tissue biomarkers to create diagnostic tests for cancer patients,
there is no question that the quality of tissue combined with advanced image analysis
and tissue mining is extremely important,” commented Ralf Huss, Chief Medical
Officer for Definiens. “This partnership allows researchers and clinicians to benefit
from the expertise of both our companies and advance personalized medicine for
treatment of patients. It will be great to see this partnership benefit not only
researchers and clinicians, but also ultimately cancer patients.”

About Indivumed:
Indivumed an ISO certified global oncology research company based in Hamburg,
Germany, has established the world’s leading Cancer Database and biobank,
retaining unique patterns of biomolecules such as RNA, DNA, and proteins as they
existed in the human body. This Cancer Database makes possible multi-omics
capabilities that will allow for characterization of samples and data such as whole
genome gene expression analysis, expression analysis of cancer relevant proteins,
expression analysis of cancer relevant phosphoproteins and bioinformatic solutions
for integrating molecular, biological and clinical information.
Indivumed’s products and services allow for in-depth understanding of the underlying
mechanisms of a patient’s cancer, addressing important demands in translational
research and molecular diagnostics to support implementation of personalized
healthcare.
For more information, please visit www.indivumed.com

About Definiens
Definiens is the pioneering provider of Tissue Phenomics® solutions for biomarker
and companion diagnostics development and commercialization. Definiens’
technology empowers smarter tissue-based diagnostics by leveraging quantitative
tissue readouts and other big data sources. By enabling the development of powerful
and precise assays for patient stratification and clinical trial enrollment, Definiens
aims to dramatically improve patient outcomes. Definiens' Tissue Phenomics
approach was awarded the 2013 Frost and Sullivan Company of the Year Award for
Global Tissue Diagnostics and Pathology Imaging.
For more information, please visit: www.definiens.com

Media contact:
Indivumed GmbH
Tel.: +49-40-4133-83-0
E-mail: press@indivumed.com

Definiens
Jonathan Moll
Tel.: +1 212 398 9680
E-mail: jmoll@affect.com

Download this press release

Back to Media